John F. Paolini

15.6k total citations · 3 hit papers
84 papers, 10.2k citations indexed

About

John F. Paolini is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, John F. Paolini has authored 84 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Cardiology and Cardiovascular Medicine, 25 papers in Surgery and 22 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in John F. Paolini's work include Pericarditis and Cardiac Tamponade (21 papers), Lipoproteins and Cardiovascular Health (19 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (12 papers). John F. Paolini is often cited by papers focused on Pericarditis and Cardiac Tamponade (21 papers), Lipoproteins and Cardiovascular Health (19 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (12 papers). John F. Paolini collaborates with scholars based in United States, Italy and United Kingdom. John F. Paolini's co-authors include Christopher C. Nessel, Kenneth W. Mahaffey, Manesh R. Patel, Jonathan L. Halperin, Richard C. Becker, Robert M. Califf, Daniel E. Singer, Keith A.A. Fox, Jonathan P. Piccini and Graeme J. Hankey and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Immunology.

In The Last Decade

John F. Paolini

82 papers receiving 9.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

2011 6.5k citations Manesh R. Patel, Kenneth W. Mahaffey et al. New England Journal of Medicine profile →
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

2011 424 citations Keith A.A. Fox, Jonathan P. Piccini et al. profile →
Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

2014 312 citations Jonathan L. Halperin, Graeme J. Hankey et al. Circulation profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
John F. Paolini	7.8k	3.8k	1.5k	1.3k	616	84	10.2k
Jun Zhu	9.6k 1.2×	3.9k 1.0×	1.6k 1.1×	1.0k 0.8×	411 0.7×	132	10.9k
Jyotsna Garg	6.9k 0.9×	3.1k 0.8×	1.7k 1.1×	1.2k 0.9×	2.0k 3.2×	22	9.7k
Pieter W. Kamphuisen	5.3k 0.7×	6.3k 1.7×	1.3k 0.8×	1.8k 1.4×	416 0.7×	224	10.7k
Harald Darius	10.7k 1.4×	4.4k 1.2×	2.0k 1.3×	2.8k 2.1×	447 0.7×	198	14.6k
Alexander Parkhomenko	6.2k 0.8×	1.5k 0.4×	802 0.5×	841 0.6×	833 1.4×	74	7.7k
Marco Alings	12.5k 1.6×	5.5k 1.5×	1.9k 1.2×	939 0.7×	141 0.2×	84	13.6k
Vittorio Pengo	6.5k 0.8×	5.8k 1.6×	1.0k 0.6×	2.3k 1.8×	385 0.6×	362	16.0k
Jonas Oldgren	19.0k 2.4×	8.1k 2.2×	2.7k 1.8×	1.7k 1.3×	284 0.5×	193	20.9k
Udaya S. Tantry	7.4k 0.9×	2.7k 0.7×	463 0.3×	4.2k 3.3×	1.0k 1.7×	261	9.7k
Shinya Goto	10.4k 1.3×	3.7k 1.0×	1.7k 1.1×	4.1k 3.2×	960 1.6×	288	14.7k

Countries citing papers authored by John F. Paolini

Since Specialization

Citations

This map shows the geographic impact of John F. Paolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Paolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Paolini more than expected).

Fields of papers citing papers by John F. Paolini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Paolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Paolini. The network helps show where John F. Paolini may publish in the future.

Co-authorship network of co-authors of John F. Paolini

This figure shows the co-authorship network connecting the top 25 collaborators of John F. Paolini. A scholar is included among the top collaborators of John F. Paolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Paolini. John F. Paolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brucato, Antonio, Allan L. Klein, Massimo Imazio, & John F. Paolini. (2024). Reply to Albulushi et al.—Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From RHAPSODY Long-term Extension. CJC Open. 6(8). 1033–1034. 1 indexed citations

Cremer, Paul, Antonio Brucato, Antonella Insalaco, et al.. (2024). Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis. European Heart Journal - Cardiovascular Imaging. 26(1). 72–79. 1 indexed citations

Samant, Manoj, John A. Ziemniak, & John F. Paolini. (2023). First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell–Dependent Antibody Response. Journal of Pharmacology and Experimental Therapeutics. 387(3). 306–314. 5 indexed citations

Corbera‐Bellalta, Marc, Sujatha Muralidharan, Georgina Espígol‐Frigolé, et al.. (2022). Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Annals of the Rheumatic Diseases. 81(4). 524–536. 39 indexed citations

Lin, David, et al.. (2021). Disease and Economic Burden Associated with Recurrent Pericarditis in a Privately Insured United States Population. Advances in Therapy. 38(10). 5127–5143. 9 indexed citations

Mauro, Adolfo G, Aldo Bonaventura, Alessandra Vecchié, et al.. (2021). The Role of NLRP3 Inflammasome in Pericarditis. JACC Basic to Translational Science. 6(2). 137–150. 68 indexed citations

Klein, Allan L., Massimo Imazio, Antonio Brucato, et al.. (2020). RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. American Heart Journal. 228. 81–90. 41 indexed citations

Klein, Allan L., Massimo Imazio, Paul Cremer, et al.. (2020). Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. New England Journal of Medicine. 384(1). 31–41. 187 indexed citations

Klein, Allan L., David Lin, Paul Cremer, et al.. (2019). Abstract 12851: Efficacy and Safety of Rilonacept in Recurrent Pericarditis: A Multicenter Phase 2 Clinical Trial. Circulation. 5 indexed citations

10.

Bonaventura, Aldo, Antonio Cannatà, Eleonora Mezzaroma, et al.. (2019). Abstract 13363: Intensification of the Inflammasome Formation in the Pericardium of Patients With Chronic Severe Pericarditis. Circulation. 4 indexed citations

11.

Kataoka, Yu, Jordan Andrews, MyNgan Duong, et al.. (2017). Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. Cardiovascular Diagnosis and Therapy. 7(3). 252–263. 42 indexed citations

12.

Kootte, Ruud S., Loek P. Smits, Fleur M. van der Valk, et al.. (2015). Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. Journal of Lipid Research. 56(3). 703–712. 73 indexed citations

13.

Tanigawa, Takahiko, Mariko Kajikawa, Hitoshi Ueda, et al.. (2012). Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation. Drug Metabolism and Pharmacokinetics. 28(1). 59–70. 86 indexed citations

14.

Mahaffey, Kenneth W., Harvey D. White, Christopher C. Nessel, et al.. (2011). Abstract 13482: Ischemic Cardiac Outcomes in Patients with AF Treated with Vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial. Circulation. 124. 3 indexed citations

15.

Patel, Manesh R., Kenneth W. Mahaffey, Jyotsna Garg, et al.. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 365(10). 883–891. 6459 indexed citations breakdown →

16.

Shah, Sukrut, R Češka, Blas Gil Extremera, et al.. (2010). Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice. 64(6). 727–738. 27 indexed citations

17.

McKenney, James M., Harold Bays, Michael J. Koren, et al.. (2010). Safety of extended-release niacin/laropiprant in patients with dyslipidemia. Journal of clinical lipidology. 4(2). 105–112.e1. 27 indexed citations

18.

Maccubbin, Darbie, Michael J. Koren, Michael Davidson, et al.. (2009). Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease. The American Journal of Cardiology. 104(1). 74–81. 55 indexed citations

19.

Kush, Debra, Hyo-Soo Kim, Ji Liu, et al.. (2009). Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia. Journal of clinical lipidology. 3(3). 179–186. 3 indexed citations

20.

Bergman, Arthur, Joanne Burke, Patrick Larson, et al.. (2006). Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects. The Journal of Clinical Pharmacology. 46(3). 321–327. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact